Biocon Limited has informed the Exchange regarding a press release dated April 21, 2026, titled “Biocon Receives Health Canada Approval of Bosaya (Denosumab) and Vevzuo (Denosumab), Biosimilars to Prolia® and Xgeva®”. |SUBJECT: Press Release
Thursday, Sep 17, 2026